Synthetic nitroimidazoles: Biological activities and mutagenicity relationships

Scientia Pharmaceutica

Volumn 77, Issue 3, 2009, Pages 497-520

  Mital, Alka ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Anti HIV activity; Antibacterial; Antifungal; Antileishmanial agents; Antimycobacterial; Trypanocidal

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; 2 ETHYL 5 NITRO 2,3 DIHYDROIMIDAZO[2,1 B][1,3]OXAZOLE; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 3 TERT BUTYL 2 HYDROXYPHENYL 5 NITRO 1 METHYL 2 IMIDAZOLYLCARBINOL; 5 NITRO 1 METHYLIMADAZOL 2 YL(2 HYDROXY 3 TERT BUTYLPHENYL)CARBINOL; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMPICILLIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; ANTILEISHMANIAL AGENT; BENZNIDAZOLE; BIFONAZOLE; CGI 17341; DIIODOHYDROXYQUIN; ECONAZOLE; FLUNIDAZOLE; ISONIAZID; KETOCONAZOLE; METRONIDAZOLE; N [[3 (4 ACETYLPHENYL) 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; NIRIDAZOLE; NITROIMIDAZOLE DERIVATIVE; NORFLOXACIN; NYSTATIN; ORNIDAZOLE; RIFAMPICIN; RONIDAZOLE; SATRANIDAZOLE; STREPTOMYCIN; TINIDAZOLE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMEBIASIS; AMES TEST; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; BALANTIDIASIS; BIOLOGICAL ACTIVITY; CARCINOGENICITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENTAMOEBA HISTOLYTICA; GIARDIA DUODENALIS; GIARDIASIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MUTAGENICITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; TRYPANOSOMA CRUZI;

EID: 70349298700     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.0907-14     Document Type: Review

References (113)

1. Celik A, Aras Ates N. The frequency of sister chromatid exchanges in cultured human peripheral blood lymphocyte treated with metronidazole in vitro. Drug Chem Toxicol. 2006; 29: 85-94. doi:10.1080/01480540500408663 (Pubitemid 43292237)
2. Upcroft JA, Campbell RW, Benakli K, Upcroft P and Vanelle P. Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob Agents Chemother. 1999; 43: 73-76. PMid:9869568 (Pubitemid 29069202)
3. Adams GE. Redox, radiation and reductive bioactivation. Radiat Res. 1992; 132: 129-139. doi:10.2307/3578516
4. Adams GE and Stratford IJ. Hypoxia-mediated nitroheterocyclic drugs in the radio- and chemotherapy of cancer. Biochem Pharmacol. 1986; 35: 71-76. doi:10.1016/0006-2952(86)90560-5
5. Adams GE and Stratford IJ. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int J Radiat Oncol Biol Phys. 1994; 29: 231-238. PMid:8195012
6. Kapoor VK, Chadha R, Venisetty PK, Prasanth S. Medicinal significance of nitroimidazoles: Some recent advances. J Sci Ind Res (India). 2003; 62: 659-665. (Pubitemid 36938463)
7. Nagarajan K, Shankar RG, Rajappa S, Shenoy ST, Costa-Pereira R. Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with anti-tubercular activity. Eur J Med Chem. 1989; 24: 631-633. doi:10.1016/0223-5234(89)90034-2
8. Gunay NS, Capan G, Ulusoy N, Ergenc N, Otuk G, Kaya D. 5-Nitroimidazole derivatives as possible antibacterial and antifungal agents. Farmaco. 1999; 54: 826-831. doi:10.1016/S0014-827X(99)00109-3 (Pubitemid 30009675)
9. Silvestri R, Artico M, De Martino G, Ragno R, Massa S, Loddo R, Murgioni C, Loi AG, LaColla P, Pani A. Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1 reverse transcriptase. J Med Chem. 2002; 45: 1567-1576. doi:10.1021/jm010904a (Pubitemid 34293523)
10. Silvestri R, Artico M, Massa S, Marceddu T, DeMontis F, LaColla P. 1-[2-(Diphenylmethoxy)ethyl]-2-methyl-5-nitroimidazole a potent lead for the design of novel NNRTIs. Bioorg Med Chem Lett. 2000; 10: 253-256. doi:10.1016/S0960-894X(99)00664-2
11. Hodgkiss RJ. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Res. 1998; 13: 687-702. PMid:9755725 (Pubitemid 28410155)
12. Hori H, Jin CZ, Kiyono M, Kasai S, Shimamura M, Inayama S. Design, synthesis, and biological activity of anti-angiogenic hypoxic cell radiosensitizer haloacetylcarbamoyl-2-nitroimidazoles. Bioorg Med Chem. 1997; 5: 591-599. doi:10.1016/S0968-0896(96)00274-X (Pubitemid 27130087)
13. Kasai S, Nagasawa H, Yamashita M, Masui M, Kuwasaka H, Oshodani T, Uto Y, Inomata T, Oka S, Inayamata S, Hori H. New antimetastatic hypoxic cell radiosensitizers: design, synthesis, and biological activities of 2-nitroimidazole-acetamide, TX-1877, and its analogues. Bioorg Med Chem. 2001; 9: 453-464. doi:10.1016/S0968-0896(00)00265-0 (Pubitemid 32244043)
14. Petray PB, Morilla MJ, Corral RS, Romero EL. In vitro activity of Etanidazole against the protozoan parasite Trypanosoma cruzi. Mem Inst Oswaldo Cruz. 2004; 99: 233-235. doi:10.1590/S0074-02762004000200021
15. Petray PB, Morilla MJ, Corral RS, Romero EL. In vitro activity of Etanidazole against the protozoan parasite Trypanosoma cruzi. Mem Inst Oswaldo Cruz. 2004; 99: 233-235. doi:10.1590/S0074-02762004000200021
16. Maeda K, Osata T, Umezawa H. A new antibiotic, azomycin. J Antibiot. 1953; 6: 182. PMid:13152032
17. Cosar C, Julou L. Activitéde l (hydroxy-2-ethyl)-1-methyl-2-nitro- 5 imidazole (8,823 R.P.) vis-à-vis des infections experimentales Trichomonas vaginalis. Ann Inst Pasteur. 1959; 96: 238-241. PMid:13627590
18. Schneider J. Traitment de la giardiase (lambliase) par le metronidazole. Bull Soc Pathol Exot Filiales. 1961; 54: 84-93. PMid:13748230
19. Powell SJ, Macleod L, Wilmot AJ, Elsdon-Dew R. Metronidazole in amoebic dysentery and amoebic liver abscess. Lancet. 1966; 288: 1329-1331. doi:10.1016/S0140-6736(66)92081-2
20. Garcia-Leverde A, De Bonila L. Clinical trials with metronidazole in human balantidiasis. Am J Trop Med Hyg. 1975; 24: 781-783. PMid:1190365
21. Townson SM, Boreham PFL, Upcroft P, Upcroft JA. Resistance to the nitroheterocyclic drugs. Acta Trop. 1994; 56: 173-194. doi:10.1016/0001-706X(94) 90062-0
22. Stanley. SL Jr. Amoebiasis. Lancet. 2003; 361: 1025-1034. doi:10.1016/S0140-6736(03)12830-9
23. Haque R, Huston CD, Hughes M, Houpt E, Petri WA Jr. Amoebiasis. N Engl J Med. 2003; 348: 1565-1573. doi:10.1056/NEJMra022710
24. Müller M. Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery. 1983; 93: 165-171. PMid:6849201
25. Edwards DI. Reduction of nitroimidazoles in vitro and DNA damage. Biochem Pharmacol. 1986; 35: 53-58. doi:10.1016/0006-2952(86)90554-X
26. Petri WA Jr. Therapy of intestinal protozoa. Trends Parasitol. 2003; 19: 523-526. doi:10.1016/j.pt.2003.09.003
27. Legator MS, Connor TH, Stoeckel M. Detection of mutagenic activity of metronidazole and niridazole in body fluids of humans and mice. Science. 1975; 188: 1118-1119. doi:10.1126/science.766186
28. Rustia M, Shubik P. Induction of lung tumors and malignant lymphomas in mice by metronidazole. J Natl Cancer Inst. 1972; 48: 721-729. PMid:5058971
29. Shubik P. Current status of chemical carcinogenesis. Proc Natl Acad Sci U S A. 1972; 69: 1052-1055. doi:10.1073/pnas.69.4.1052
30. Boyer JH. Nitroazoles. VCH Publishers, Inc., Deerfield Beach, FL, 1986: 165-166 and references cited therein.
31. Goldman P. The development of 5-nitroimidazoles for the treatment and prophylaxis of anaerobic bacterial infections. J Antimicrob Chemother. 1982; 10 (Suppl.): A23-A33. doi:10.1093/jac/10.suppl-A.23
32. Nagarajan K, Arya VP, George T, Sudarsanam V, Shah RK, Goud AN, Shenov SJ, Honkan V, Kulkarni YS and Rao ML. Nitroimidazoles. IV. 1-1-Methyl-5- nitroimidazolyl (2)-2-oxo-3-sulphonyl (carbamoylthiocarbamoyl) tetrahydro imidazoles. Ind J Chem. 1982; 21: 928-940.
33. Ray DK, Chatterjee DK, Tendulkar JS. Comparative efficacy of GO 10213 and some nitroimidazoles against Trichomonas vaginalis and T. foetus in mice infected subcutaneously. Ann Trop Med Parasitol. 1982; 76: 175-178. PMid:6979983
34. Ray DK, Tendulkar JS, Shrivastava VB, Datta AK, Nagarajan K. A metronidazole-resistant strain of Trichomonas vaginalis and its sensitivity to GO 10213. J Antimicrob Chemother. 1984; 14: 423-426. doi:10.1093/jac/14.4.423
35. Hof H, Stroder J. Antibacterial activity of GO 10213, a nitroimidazole derivative. Antimicrob Agents Chemother. 1986; 29: 953-954. PMid:3729357 (Pubitemid 16118350)
36. Shafiee A, Sayadi A, Roozbahani MH, Foroumadi A, Kamal F. Synthesis and in vitro antimicrobial evaluation of 5-(1-methyl-5-nitro-2-imidazolyl)-4H-1, 2, 4-triazoles. Arch Pharm. 2002; 335: 495-499. doi:10.1002/ardp.200290004
37. Bagan ES, Miwa GT. Uniquely non-mutagenic substituted nitroimidazole. 1988 US 4,728,664.
38. Miwa GT, Wang Wen-Jen R, Walsh JS. Non-mutagenic 1,2-disubstituted-4- nitroimidazole compounds useful as antiprotozoal agents. 1987 US 4,675, 337.
39. Scalesiani JBA, Calle YB. 1-Methyl-5-nitro-imidazoline derivatives and therapeutic compositions which contain them as active principle. 1983 EP 0103100-A (8413).
40. Walsh JS, Wang R, Bagan E, Wang CC, Wislocki P, Miwa GT. Structural alterations that differentially affect the mutagenic and antitrichomonal activities of 5-nitroimidazoles. J Med Chem 1987; 30: 150-156. doi:10.1021/jm00384a025 (Pubitemid 17221631)
41. Tessitore PT. New 2-(1-alkyl-5-nitro)-imidazolyl-1-(2-hydroxy-5-alkyl)- phenyl carbinols, method for the preparation thereof and pharmaceutical compositions containing them. 1983 EP 111,657.
42. Fudan D. Antibacterial 5-Nitro-1-methyl-imidazolyl-3-terbutyl-2-hydroxy- aryl-carbinols. (Euroresearch S.R.L.). 1992 EP 535,528.
43. Arredondo Y, Moreno-Mafias M, Pleixats R, Palacin C, Raga MM, Castelló JM, Ortiz JA. Preparation, antimicrobial evaluation and mutagenicity of differently substituted [2-hydroxyaryl]-[1-methyl-5-nitro-1H-2- imidazolyl]methanols. Bioorg Med Chem Lett. 1996; 6: 1781-1784. doi:10.1016/0960-894X(96)00317-4 (Pubitemid 26253876)
44. Dubini F, Riviera L, Cocuzza C, Bellotti MG. Antibacterial, antimycotic and trichomonicidal activity of a new nitroimidazole EU 11100. J Chemother. 1992; 4: 342-346. PMid:1287136 (Pubitemid 23030538)
45. Hadj-esfandiari N, Navidpour L, Shadnia H, Amini M, Samadi N, Faramarzi MA & Shafieea A. Synthesis, antibacterial activity, and quantitative structure-activity relationships of new (Z)-2-(nitroimidazolylmethylene)-3(2H)- benzofuranone derivatives. Bioorg Med Chem Lett. 2007; 17: 6354-6363. doi:10.1016/j.bmcl.2007.09.062 (Pubitemid 47552849)
46. Khabnadideh S, Rezaei Z, Khalafi-Nezhad A, Bahrinajafi R, Mohamadi R, Farrokhroz AA. Synthesis of N-alkylated derivatives of imidazole as antibacterial agents. Bioorg Med Chem Lett. 2003; 13: 2863-2865. doi:10.1016/S0960-894X(03)00591-2 (Pubitemid 37386239)
47. Crozet MD, Botta C, Gasquet M, Curti C, Rémusat V, Hutter S, Chapelle O, Azas N, De Méo M, Vanelle P. Lowering of 5-nitroimidazole's mutagenicity: Towards optimal antiparasitic pharmacophore. Eur J Med Chem. 2009; 44: 653-659. doi:10.1016/j.ejmech.2008.05.015
48. Hrelia P, Fimognari C, Maffei F, Brighenti B, Garuti L, Burnelli S, Cantelli-Forti G. Synthesis, metabolism and structure-mutagenicity relationships of novel 4-nitro-(imidazoles and pyrazoles) in Salmonella typhimurium. Mutat Res. 1998; 397: 293-301. doi:10.1016/S0027-5107(97)00229-7
49. Purohit V, Basu AK. Mutagenicity of nitroaromatic compounds. Chem Res Toxicol. 2000; 8: 673-692. doi:10.1021/tx000002x
50. De Méo M, Vanelle P, Bernadini E, Laget M, Maldonado J, Jentzer O, Crozet MP, Duménil G. Evaluation of the mutagenic and genotoxic activities of 48 nitroimidazoles and related imidazole derivates by the Ames test and the SOS chromotest. Environ Mol Mutagen. 1992; 19: 167-181. PMid:1541258
51. Dobiás L, Cerná M, Rössner P, Srám R. Genotoxicity and carcinogenicity of metronidazole. Environ Mutagen. 1994; 317: 177-194. Pmid:7515153
52. Mirzaei J, Siavoshi F, Emami S, Safari F, Khoshayand MR, Shafiee A, Foroumadi A. Synthesis and in vitro anti-Helicobacter pylori activity of N-[5-(5-nitro-2-heteroaryl)-1,3,4-thiadiazol-2-yl]thiomorpholines and related compounds. Eur J Med Chem. 2008; 43: 1575-1580. doi:10.1016/j.ejmech.2007.11.019
53. Dunn LA and Boreham PFL. The in-vitro activity of drugs against Blastocystis hominis. J Antimicrob Chemother. 1991; 27: 507-516. doi:10.1093/jac/27.4.507
54. Gunay NS, Capan G, Ulusoy N, Ergenc N, Otuk G and Kaya D. Nitroimidazole derivatives as possible antibacterial and antifungal agents. Farmaco. 1999; 54: 826-831. doi:10.1016/S0014-827X(99)00109-3 (Pubitemid 30009675)
55. Sun Z and Zhang Y. Antituberculosis activity of certain antifungal and antihelmintic drugs. Tub Lung Dis. 1999; 79: 319-320. doi:10.1054/tuld.1999.0212 (Pubitemid 29479132)
56. Olender D, Zwawiak J, Lukianchuk V, Lesyk R, Kropacz A, Fojutowski A, Zaprutko L. Synthesis of some N-substituted nitroimidazole derivatives as potential antioxidant and antifungal agents. Eur J Med Chem. 2009; 44: 645-652. doi:10.1016/j.ejmech.2008.05.016
57. Cavalleri B, Ballotta R, Arioli V, Lancini G. New 5-substituted 1-alkyl-2-nitroimidazoles. J Med Chem. 1973; 16: 557-560. doi:10.1021/ jm00263a035
58. Cavalleri B, Volpe G, Arioli V. Synthesis and biological activity of some vinyl-substituted 2-nitroimidazoles. J Med Chem. 1977; 20: 656-660. doi:10.1021/jm00215a007 (Pubitemid 8095437)
59. Cavalleri B, Volpe G, Arioli V, Parenti F. Synthesis and biological activity of some 2-aminoimidazoles. Arzneimittelforschung. 1977; 27: 1889-1895. PMid:579099
60. Cavalleri B, Volpe G, Ripamonti A, Arioli V. 1-Methyl-2-nitroimidazol-5- yl derivatives. IIIrd communication. Arzneimittelforschung. 1977; 27: 1131-1134. PMid:578425
61. Cavalleri B, Volpe G, Arioli V, Lancini GC. 1-Methyl-2-nitroimidazol-5-yl derivatives. IVth Communication. Arzneimittelforschung. 1977; 27: 1391-1392. PMid:332192
62. Sehgal RK, Agrawal KC. Novel nitroimidazo[2,1-b] oxazole formation from reaction of 2, 4(5)-dinitroimidazole with oxiranes (1). J Heterocyclic Chem. 1979; 16: 1499-1500. doi:10.1002/jhet.5570160743
63. Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathan N, Bhatt AD, Rittel W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1993; 37: 183-186. PMid:8452346
64. Li X, Manjunatha UH, Goodwin MB, Knox JE, Lipinski CA, Keller TH, Barry CE III and Dowd CS. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6, 7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824. Bioorg Med Chem Lett. 2008; 18: 2256-2262. doi:10.1016/j.bmcl.2008.03.011
65. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. OPC-67683, a Nitro-Dihydro-Imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006; 3: 2131-2144. doi:10.1371/journal.pmed.0030466
66. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE III, Baker WR. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000; 405: 962-966. doi:10.1038/35016103 (Pubitemid 30435054)
67. Barry CE III, Boshoff HI, Dowd CS. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des. 2004; 10: 3239-3262. doi:10.2174/1381612043383214
68. Jackson CJ, Lamb DC, Kelly DE, Kelly SL. Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis. FEMS Microbiol Lett. 2000; 192: 159-162. doi:10.1111/j.1574-6968.2000.tb09375.x
69. Mamolo MG, Zampieri D, Falagiani V, Vio L, Banfi E. Synthesis and antifungal activity of (+/-)-1-(5-aryl-3-pyridin-2-yl-4,5-dihydro-pyrazol-1-yl)- 2-imidazol-1-yl-ethanone. derivatives. Farmaco. 2003; 58: 315-322. doi:10.1016/S0014-827X(02)00006-X
70. Walczak K, Gondela A, Suwinski J. Synthesis and anti-tuberculosis activity of N-aryl-C-nitroazoles. Eur J Med Chem. 2004; 39: 849-853. doi:10.1016/j.ejmech.2004.06.014
71. Foroumadi A, Soltani F, Jabini R, Moshafi MH, Rasnani FM. Antituberculosis Agents X. Synthesis and evaluation of in vitro antituberculosis activity of 2-(5-nitro-2-furyl)- and 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-1,3, 4-thiadiazole Derivatives. Arch Pharm Res. 2004; 27: 502-506. doi:10.1007/BF02980122
72. Foroumadi, A.; Mirzaei, M.; Shafiee A. Antituberculosis agents II: Evaluation of in vitro antituberculosis activity and cytotoxicity of some 2-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole derivatives. Farmaco. 2001; 56: 621-623. doi:10.1016/S0014-827X(01)01099-0
73. Buschini A, Giordani F, Northfleet de Albuquerque C, Pellacani C, Pelosi G, Rossi C, Araujo TM, Zucchi D, Poli P. Trypanocidal nitroimidazole derivatives: Relationships among chemical structure and genotoxic activity. Biochem Pharmacol. 2007; 73: 1537-1547. doi:10.1016/j.bcp.2007.01.024 (Pubitemid 46546382)
74. Bouteille B, Marie-Daragon A, Chauvière G, De Albuquerque C, Enanga B, Darde M-L et al. Effect of megazol on Trypanosoma brucei brucei acute and subacute infections in Swiss mice. Acta Trop. 1995; 60: 73-80. doi:10.1016/0001-706X(95)00109-R
75. Enanga B, Keita M, Chauviere G, Dumas M, Bouteille B. Megazol combined with suramin: a chemotherapy regimen which reversed the CNS pathology in a model of human African trypanosomiasis in mice. Trop Med Int Health. 1998; 3: 736-741. PMid:9754669 (Pubitemid 28450437)
76. Viode C, Bettache N, Cenas N, Krauth-Siegel RL, Chauviere G, Bakalara N et al. Enzymatic reduction studies of nitroheterocycles. Biochem Pharmacol. 1999; 57: 549-557. doi:10.1016/S0006-2952(98)00324-4
77. Chauviere G, Bouteille B, Enanga B, de Albuquerque C, Croft SL, Dumas M et al. Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead. J Med Chem. 2003; 46: 427-440. doi:10.1021/jm021030a (Pubitemid 36139794)
78. Voogd CE, Van der Stel JJ, Jacobs JJ. The mutagenic action of nitroimidazoles. II. Effects of 2-nitroimidazoles. Mutat Res. 1975; 31: 149-152. doi:10.1016/0165-1161(75)90083-7
79. Melo ME, Ferreira LC. Screening the mutagenic activities of commonly used antiparasite drugs by the Simultes, a simplified Salmonella/microsome plate incorporation assay. Rev Inst Med Trop Sao Paulo. 1990; 32: 269-274. doi:10.1590/S0036-46651990000400006
80. Bouteille B, Chauvière G. Implication du megasol dans la chimiotherapie des trypanosomosis. Med Trop. 1999; 59: 321-330. PMid:10816740
81. Docampo R, Moreno SN. Free radical metabolites in the mode of action of chemotherapeutic agents and phagocytic cells on Trypanosoma cruzi. Rev Infect Dis. 1984; 6: 223-238. PMid:6328615
82. Poli P, de Mello MA, Buschini A, Mortara RA, de Albuquerque NC, da Silva S et al. Cytotoxic and genotoxic effects of megazol, an anti-Chagas' disease drug, assessed by different short-term tests. Biochem Pharmacol. 2002; 64: 1617-1627. doi:10.1016/S0006-2952(02)01390-4 (Pubitemid 35333423)
83. Nesslany F, Brugier S, Mouries MA, Le Curieux F, Marzin D. In vitro and in vivo chromosomal aberrations induced by megazol. Mutat Res. 2004; 560: 147-158. doi:10.1016/j.mrgentox.2004.02.013
84. Ferreira RC, Ferreira LC. CL 64,855, a potent anti-Trypanosoma cruzi drug, is also mutagenic in the Salmonella/microsome assay. Mem Inst Oswaldo Cruz. 1986; 81: 49-52. doi:10.1590/S0074-02761986000100006
85. Borowy NK, Nelson RT, Hirumi H, Brun R, Waithaka HK, Schwartz D, Polak A. RO150216 a nitroimidazole compound active against human and animal pathogenic African trypanosomes. Ann Trop Med Parasitol. 1988; 82: 13-19. PMid:3401068 (Pubitemid 18111063)
86. McCoy EC, Rosenkranz HR, Mermelstein R. Evidence for the existence of a family of bacterial nitroreductases capable of activating nitrated polycyclics to mutagens. Environ Mol Mutagen. 1981; 3: 421-427. doi:10.1002/em.2860030403 (Pubitemid 11005379)
87. Orr JC, Bryant DW, McCalla DR, Quilliam MA. Dinitropyrene-resistant Salmonella typhimurium are deficient in n acetyl-CoA-acetyl-transferase. Chem Biol Interact. 1985; 54: 281-288. doi:10.1016/S0009-2797(85)80169-1
88. 2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4-and 5-(2-aminoethyl) thiazoles. J Med Chem. 1992; 35: 3239-3246. doi:10.1021/jm00095a021
89. Kovalainen JT, Christiaans JAM, Kotisaari S, Laitinen JT, Männistö PT, Tuomisto L, Gynther J. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-amino-3-(1H-imidazol-4(5)-yl) propyl ether derivatives. J Med Chem. 1999; 42: 1193-1202. doi:10.1021/jm980408v
90. Farsch SC, Nick JA, Fadok VA, Bratton DL, Worthen GS, Henson PM. p38 Mitogen-activated protein kinase-dependent and -independent intracellular signal transduction pathways leading to apoptosis in human neutrophils. J Biol Chem. 1998; 273: 8389-8397. doi:10.1074/jbc.273.14.8389
91. Salerno L, Sorrenti V, Guerrera F, Sarva MC, Siracusa MA, Di Giacomo C, Vanella A. N-substituted-imidazoles as inhibitors of nitric oxide synthase: a preliminary screening. Pharmazie. 1999; 54: 685-690.
92. Castelli M, Malagoli M, Lupo L, Roffia S, Paolucci F, Cermelli C, Zanca A, Baggio G. Cytotoxicity and probable mechanism of action of sulphimidazole. J Antimicrob Chemother. 2000; 46: 541-550. doi:10.1093/jac/46.4.541 (Pubitemid 30793862)
93. Adams GE, Clarke ED, Flockhart IR, Jacobs RS, Sehmi DS, Stratford P, Wardman IJ, Watts ME, Parrick J, Wallace RG, Smithen CE. Structure-activity relationships in the development of hypoxic cell radiosensitizers I. Sensitization efficiency. Int J Radiat Biol Relat Stud Phys Chem Med. 1979; 35: 133-150. PMid:312783 (Pubitemid 9111460)
94. Noker P, Simpson-Herren L, Wagoner SD. Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors. Cancer Chemother Pharm. 1987; 20: 188-192. PMid:3677296 (Pubitemid 17163391)
95. Al-Soud YA, Al-Masoudi NA, Hassan HG, Clercq ED, Pannecouque C. Nitroimidazoles. V. Synthesis and anti-HIV evaluation of new 5-substituted piperazinyl-4-nitroimidazole derivatives. Acta Pharm. 2007; 57: 379-393. doi:10.2478/v10007-007-0031-7
96. Silvestri R, Artico M, Massa S, Marceddu T, Montis F De and Colla P La. 1-[2-(diphenylmethoxy)ethyl]-2-methyl-5-nitroimidazole: a potent lead for the design of novel NNRTIs. Bioorg Med Chem Lett. 2000; 10: 253-256. doi:10.1016/S0960-894X(99)00664-2
97. Martino GDe, Regina GLa, Pasquali ADi, Ragno R, Bergamini A, Ciaprini C, Sinistro A, Maga G, Crespan E, Artico M and Silvestri R. Novel 1-[2-(Diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: A structure-activity relationship investigation. J Med Chem. 2005; 48: 4378-4388. doi:10.1021/jm050273a (Pubitemid 40884940)
98. Poorrajab F, Ardestani SK, Emami S, Behrouzi-Fardmoghadam M, Shafiee A, Foroumadi, A. Nitroimidazolyl-1,3,4-thiadiazole-based anti-leishmanial agents: Synthesis and in vitro biological evaluation. Eur J Med Chem. 2009; 44: 1758-1762. doi:10.1016/j.ejmech.2008.03.039
99. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994; 6: 509-518. PMid:7620219
100. Brezden CB, McClelland RA and Rauth AM. Mechanism of the selective hypoxic cytotoxicity of 1-methyl-2-nitroimidazole. Biochem Pharmacol. 1994; 48: 361-370. doi:10.1016/0006-2952(94)90108-2 (Pubitemid 24243979)
101. Koch CJ, Evans SM and Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer. 1995; 72: 869-874. PMid:7547233
102. Taylor YC and Rauth AM. Oxygen tension, cellular respiration, and redox state as variables influencing the cytotoxicity of the radiosensitizer misonidazole. Radiat Res. 1982; 91: 104-123. doi:10.2307/3575819
103. Wardman P. The use of nitroaromatic compounds as hypoxic cell radiosensitizers. Curr Top Radiat Res Q. 1977; 11: 347-398. PMid:330116
104. Uto Y, Nagasawa H, Jin C-Zhe, Nakayama S, Tanaka A, Kiyoi S, Nakashima H, Shimamura M, Inayama S, Fujiwara T, Takeuchi Y, Uehara Y, Kirk KL, Nakata E and Hori H. Design of antiangiogenic hypoxic cell radiosensitizers: 2-Nitroimidazoles containing a 2-aminomethylene-4-cyclopentene-1,3-dione moiety. Bioorg Med Chem. 2008; 16: 6042-6053. doi:10.1016/j.bmc.2008.04.041 (Pubitemid 351758833)
105. Edwards DI. Nitroimidazole drugs-action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother. 1993; 31: 9-20. doi:10.1093/jac/31.1.9
106. Ehlhardt WJ, Beaulieu BB Jr, Goldman P. Mammalian cell toxicity and bacterial mutagenicity of nitrosoimidazoles. Biochem Pharmacol. 1988; 37: 2603-2606. doi:10.1016/0006-2952(88)90252-3 (Pubitemid 18162373)
107. Roe FJ. Metronidazole: review of uses and toxicity. J Antimicrob Chemother. 1977; 3: 205-212. doi:10.1093/jac/3.3.205
108. Roe FJ. Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic, and teratogenic potential. Surgery. 1983; 93: 158-164. PMid:6336861
109. Roe FJ. Safety of nitroimidazoles. Scand J Infect Dis Suppl. 1985; 46: 72-81. PMid:3865353
110. Voogd CE. On the mutagenicity of nitroimidazoles. Mutat Res. 1981; 86: 243-277. PMid:6457989
111. Mason RP, Josephy PP. Free radical mechanisms of nitroreductase. In: D. E. Rickert (Ed.). Toxicity of Nitroaromatic Compounds, Hemisphere, Washington DC, 1985: 121-140.
112. Lindmark DG, Muller M. Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles. Antimicrob Agents Chemother. 1976; 10: 476-482. PMid:791102
113. Biaglow JE, Varnes ME, Roizin-Towle L, Clark EP, Epp ER, Astor MB and Hall EJ. Biochemistry of reduction of nitro heterocycles. Biochem Pharmacol. 1986; 35: 77-90. doi:10.1016/0006-2952(86)90561-7